within Pharmacolibrary.Drugs.ATC.V;

model V09DA05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2e-06,
    adminDuration  = 600,
    adminMass      = 74 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V09DA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Technetium (99mTc) galtifenin is a radiopharmaceutical used in nuclear medicine primarily as a hepatobiliary imaging agent to assess liver and gallbladder function. It is used in diagnostic imaging (cholescintigraphy) to evaluate biliary tract patency and gallbladder ejection fraction. This drug is not approved or widely used in clinical practice today, with limited historical or investigational usage.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data in humans or animals could be found. All pharmacokinetic parameters are estimated based on the class of technetium-99m labeled hepatobiliary agents and general properties of similar compounds.</p><h4>References</h4><ol><li><p>Shanthly, N, et al., &amp; Thakur, ML (2006). 99mTc-Fanolesomab: affinity, pharmacokinetics and preliminary evaluation. <i>The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...</i> 50(2) 104–112. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16770300/&quot;>https://pubmed.ncbi.nlm.nih.gov/16770300</a></p></li><li><p>Huston, JS, et al., &amp; Weiner, LM (1996). Single-chain Fv radioimmunotargeting. <i>The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)</i> 40(3) 320–333. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8961808/&quot;>https://pubmed.ncbi.nlm.nih.gov/8961808</a></p></li><li><p>Decristoforo, C, &amp; Mather, SJ (2002). The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides. <i>The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)</i> 46(3) 195–205. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12134136/&quot;>https://pubmed.ncbi.nlm.nih.gov/12134136</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V09DA05;
